Tag: Cytokinetics

Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Results Will Be Presented in Late Breaking Clinical Trial Session at AHA Scientific Sessions 2020 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Oct. 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, […]

Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure

Heart Failure Patients in Phase 3 Clinical Trial of Omecamtiv Mecarbil Are at High Risk of Cardiovascular Events and Symptom Burden SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that a manuscript detailing the baseline characteristics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase […]

Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals

Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 13th, 2020 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the third annual Cytokinetics Communications Fellowship Grant program. The Communications Fellowship program provides a total of $100,000 […]

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271

Company Advances Second Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered […]

Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy

Company Makes Long-term Commitment to Outcomes Research in HCM SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy (HCM) focused on improving predictive measures […]

Cytokinetics Reports Second Quarter 2020 Financial Results

Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capital to Support Commercial Development and Pipeline Expansion; Company Expects to End 2020 With More Than $500 Million Cash SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported […]

Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day

Topline Results from GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4 Licensing Collaboration and Royalty Monetization Deals with Xi Jing Pharmaceuticals and RTW Investments Accelerate and Expand Development of CK-3773274, Next Generation Cardiac Myosin Inhibitor Leveraging Partnerships to Finance Build of Commercial Business SOUTH SAN FRANCISCO, […]

Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

$250 Million in Committed Capital to Cytokinetics; Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceuticals to Develop & Commercialize in China RTW Provides Access to Capital to Cytokinetics to Fund Global Development in Exchange for Potential Royalties and Agrees to Purchase Royalty on Mavacamten Company to Host […]

FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure

Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin […]